nVerses Capital LLC Has $62,000 Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

nVerses Capital LLC lowered its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 77.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 500 shares of the biotechnology company’s stock after selling 1,700 shares during the quarter. nVerses Capital LLC’s holdings in Sarepta Therapeutics were worth $62,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of SRPT. Mather Group LLC. bought a new stake in shares of Sarepta Therapeutics in the 1st quarter worth $28,000. Riggs Asset Managment Co. Inc. boosted its holdings in Sarepta Therapeutics by 125.0% during the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 125 shares during the last quarter. Innealta Capital LLC bought a new stake in Sarepta Therapeutics in the 2nd quarter worth about $31,000. New Covenant Trust Company N.A. purchased a new stake in Sarepta Therapeutics in the 1st quarter valued at about $32,000. Finally, GAMMA Investing LLC lifted its position in shares of Sarepta Therapeutics by 37.0% during the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after buying an additional 87 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the transaction, the chief financial officer now directly owns 33,946 shares in the company, valued at approximately $4,662,822.56. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Michael Andrew Chambers purchased 37,038 shares of the company’s stock in a transaction on Friday, August 16th. The stock was purchased at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the purchase, the director now directly owns 284,034 shares in the company, valued at approximately $38,003,749.20. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Ian Michael Estepan sold 5,985 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the transaction, the chief financial officer now directly owns 33,946 shares in the company, valued at approximately $4,662,822.56. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Stock Up 0.2 %

Shares of NASDAQ:SRPT opened at $127.31 on Tuesday. The firm has a fifty day moving average price of $129.00 and a two-hundred day moving average price of $132.39. The company has a market cap of $12.03 billion, a price-to-earnings ratio of 1,157.36 and a beta of 0.82. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19. Sarepta Therapeutics, Inc. has a one year low of $55.25 and a one year high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.06. The company had revenue of $362.90 million during the quarter, compared to analyst estimates of $394.38 million. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The firm’s quarterly revenue was up 38.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.27) earnings per share. Analysts anticipate that Sarepta Therapeutics, Inc. will post 1.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on SRPT. Barclays decreased their price target on Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. Citigroup cut their price target on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. Raymond James restated an “outperform” rating and set a $150.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, October 10th. Evercore ISI upgraded shares of Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and dropped their target price for the company from $185.00 to $179.00 in a research note on Thursday, August 8th. Finally, Leerink Partners lifted their price target on shares of Sarepta Therapeutics from $165.00 to $230.00 and gave the stock an “outperform” rating in a report on Monday, June 24th. Two equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $182.95.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.